Anika Loses Line of Sight on Multi-Year Growth Targets

Anika Therapeutics reported 4Q21 orthopedic sales of $33 million, +10% vs. 4Q20. For the full year, the company generated $138.1 million in orthopedic sales, +12.8% vs. 2020.

The company's viscosupplement business drove fourth-quarter growth largely due to favorable ordering patterns. The rest of Anika's implant portfolio struggled against...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us